Application Note: Measuring PD-L1 Expression in Breast Cancer Cell Lines with AlphaLISA Technology

In basal-like breast cancer, PD-L1 expression is associated with tumor severity and poor prognosis. Basal-like breast tumors show a prominent lymphocytic infiltration and an ability to adapt to Interferon gamma (IFN-γ)-mediated responses to evade immunity via upregulation of PD-L1 protein.

Several anti-PD-1 or PD-L1 monoclonal antibodies have been developed to treat cancers by blocking PD-1/PD-L1 complex formation. However, there remains a need for more robust, rapid, high-throughput assays to identify and qualify novel inhibitors of PD-1/PD-L1 binding and to detect both binding partners.

Find out how AlphaLISA® assay technology, combined with the EnVision® multilabel plate reader, provides a fast, powerful, homogeneous platform for screening potential inhibitors of PD-L1 expression in human cells in this application note.

Summary of Application Note
In this application note you will learn:
  • The benefits of using AlphaLISA technology for identifying and characterizing endogenous PD-L1 expression in cells
  • How AlphaLISA technology can be used to assess differences in expression between cells from different tumor origins
  • How treatment of cancer cell lines with IFN-γ modulates PD-L1 biomarker expression
  • That PD-L1 upregulation via IFN-γ signaling is controlled through the JAK1/2 pathway and phosphorylation of STAT1 at Tyr701

Complete the form below to download this application note